
AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Cohu, you need to believe its test platforms can stay essential as AI data center and power electronics requirements become more complex, while the business works through semiconductor cycles and current losses. The US$5,000,000 DiamondX GaN order supports the AI infrastructure angle by tying Cohu to power conversion inside AI data centers, but does not remove key near term risks around customer concentration, qualification timing for new platforms and the volatility that comes with an unprofitable, highly cyclical end market mix.
Against that backdrop, the recent shareholder vote to increase authorized common shares from 90 million to 150 million and approve new equity and employee stock purchase plans is worth watching. It sits alongside ongoing ESOP related shelf registrations and could matter for investors who are already weighing catalysts such as growing AI and HPC exposure against risks like underutilized capacity, elevated R&D and potential dilution while earnings remain negative.
Yet behind the AI test wins and product momentum, one risk investors should be aware of is that Cohu’s growing customer concentration means...
Read the full narrative on Cohu (it's free!)
Cohu's narrative projects $817.1 million revenue and $48.9 million earnings by 2029. This requires 19.3% yearly revenue growth and a $104.4 million earnings increase from -$55.5 million today.
Uncover how Cohu's forecasts yield a $57.43 fair value, a 26% upside to its current price.
Before this DiamondX AI power-device win, the most pessimistic analysts were still assuming about 17.2% annual revenue growth and earnings of US$36.6 million by 2029, yet they worried that heavy focus on AI handlers tied to a few large programs could leave Cohu with underused capacity if spending cools, so this new order may or may not shift that more cautious story.
Explore 2 other fair value estimates on Cohu - why the stock might be worth as much as 67% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com